HRPC(SH:600829)2023-04-20 16:00Financial Performance - The company's operating revenue for Q1 2023 was CNY 2,653,397,225.81, representing a year-on-year increase of 13.94%[3] - Net profit attributable to shareholders for the same period was CNY 71,786,436.01, reflecting a significant year-on-year growth of 55.62%[6] - The gross profit margin improved to 9.17%, an increase of 0.47 percentage points compared to the previous year, contributing to the rise in net profit[6] - Total operating revenue for Q1 2023 reached CNY 2,653,397,225.81, an increase of 13.9% compared to CNY 2,328,665,371.67 in Q1 2022[19] - Total operating costs for Q1 2023 were CNY 2,550,439,328.97, up from CNY 2,263,690,794.26 in Q1 2022, reflecting a growth of 12.7%[19] - Net profit for Q1 2023 was CNY 72,129,935.24, representing a significant increase of 56.6% from CNY 46,087,379.78 in Q1 2022[20] - Earnings per share (EPS) for Q1 2023 was CNY 0.1238, compared to CNY 0.0795 in Q1 2022, indicating a growth of 55.7%[21] Assets and Liabilities - The total assets at the end of the reporting period were CNY 7,136,692,843.36, up 1.10% from the end of the previous year[4] - The company's total liabilities as of Q1 2023 amounted to CNY 4,601,926,674.82, slightly up from CNY 4,596,080,968.91 in the previous year[17] - The total equity attributable to shareholders reached CNY 2,535,484,151.33, an increase from CNY 2,463,697,715.32 in Q1 2022, marking a growth of 2.9%[17] - The total current liabilities were CNY 4,427,082,345.27, showing a slight decrease from CNY 4,431,327,072.43 in the previous year[17] - The total current assets amounted to approximately RMB 6.63 billion, an increase from RMB 6.55 billion, reflecting a growth of about 1.2%[15] Cash Flow - The company reported a net cash flow from operating activities of -CNY 38,881,437.25, which is not comparable due to the nature of the cash flow[3] - In Q1 2023, the cash inflow from operating activities was CNY 2,535,272,930.90, an increase of 27.2% compared to CNY 1,993,303,465.14 in Q1 2022[22] - The net cash flow from operating activities was CNY -38,881,437.25, slightly improved from CNY -39,018,919.18 in the same period last year[24] - The total cash outflow from operating activities was CNY 2,574,154,368.15, up from CNY 2,032,322,384.32 in Q1 2022, reflecting a 27% increase[24] - The cash and cash equivalents at the end of Q1 2023 amounted to CNY 993,250,103.02, compared to CNY 778,777,950.28 at the end of Q1 2022, marking a 27.5% increase[26] Expenses - The company’s financial expenses decreased by 58.38%, primarily due to the optimization of financing and lower interest expenses[8] - Research and development expenses for Q1 2023 were CNY 6,036,772.45, down from CNY 14,505,000.01 in Q1 2022, indicating a reduction of 58.4%[20] - The company reported a decrease in financial expenses, which were CNY 6,036,772.45 in Q1 2023 compared to CNY 14,505,000.01 in Q1 2022[20] - The company's management expenses increased significantly to CNY 632,284.54 in Q1 2023 from CNY 389,050.95 in Q1 2022, indicating a rise of 62.5%[29] Legal Matters - The company reported a significant legal matter regarding a construction contract dispute, with a previous judgment requiring payment of over RMB 32.55 million, which is currently under review[12][13] - The company has committed to closely monitoring the ongoing legal proceedings and will continue to fulfill its information disclosure obligations[12] Strategic Focus - The company is focusing on expanding its wholesale and retail segments, enhancing brand influence through specialized pharmacies[5] - The company has implemented various measures to improve sales revenue and gross profit margin, leading to a substantial increase in net profit[6] - The company has not disclosed any new product developments or market expansion strategies in the current report[12] - There were no significant updates on mergers or acquisitions during the reporting period[12]